Ark Yongkang (06086) announces: Mr. Xie Fangmin has been appointed as a non-executive director, and the "AI + chronic disease management" strategy is moving forward firmly.

ArcheCloud Holdings Limited (06086) announced on December 8, 2025, that Mr. Xie Fangmin has resigned as the Chairman of the Board, Chairman and Member of the Nomination Committee, Chief Executive Officer, and Authorized Representative of the company, effective from December 7, 2025, in order to devote more time to his personal affairs and related arrangements. The Board respects his decision and sincerely thanks Mr. Xie Fangmin for his outstanding leadership and valuable contributions to the company during his tenure. Mr. Xie Fangmin has been reappointed as a Non-Executive Director by the Board and will continue to provide guidance to the company with his wealth of experience. The Board has decided to appoint the current Non-Executive Director, Mr. David McKee HAND, as the Chairman, effective from December 7, 2025. The Board has instructed the Nomination Committee to formally search for a new Chief Executive Officer and consider both internal and external candidates to find the most suitable successor to lead the company forward. These arrangements are being carried out orderly under the company's sound governance mechanism, and the existing strategic and daily business operations will not be affected. The Board and the new leadership team will continue to focus on driving the steady development of the company. As the founder and leader, Mr. Xie Fangmin has been focusing on the company's long-term development and deepening strategic layout since the establishment of ArcheCloud in 2015. His innovative "H2H (Hospital to Home)" model and strategic direction of integrating AI and healthcare in recent years have laid a solid foundation for the company's development. At a critical moment of transformation and upgrade in the pharmaceutical industry, Mr. Xie Fangmin led the team to break through bottlenecks and upgrade the company from a pharmaceutical e-commerce to a leading enterprise in "AI + chronic disease management." The company was successfully listed on the main board of the Hong Kong Stock Exchange in 2024. His contributions to the company are indelible, and all employees of the company extend their highest respect and sincere thanks to Mr. Xie Fangmin. It is reported that Mr. Xie Fangmin has a deep bond with ArcheCloud. After his transfer to a Non-Executive Director, he will continue to guide the company's development with his profound industry experience and strategic vision, helping the company continue to advance steadily towards the goal of being China's leading smart health services platform. With the wind at our backs, ArcheCloud will continue to focus on online chronic disease management, serving millions of patients through "AI + chronic disease management" and striving to build a win-win ecosystem for chronic disease services. With practical actions injecting lasting power into the "Healthy China 2030" goal, we will continue to write a new chapter in the smart health industry with a more dynamic posture.